Coronaviruses main proteases and their inhibitors

Area of Science:

• Virology
• Drug Discovery
• Medicinal Chemistry

Background:

• The SARS-CoV-2 main protease (Mpro) is crucial for viral replication, processing essential non-structural proteins.
• Its high conservation across coronaviruses and lack of human homologs make Mpro an ideal antiviral target.

Purpose of the Study:

• To provide a comprehensive overview of Mpro inhibitors for SARS-CoV-2.
• To discuss current drug discovery efforts, challenges, and future directions in Mpro-targeted therapeutics.

Main Methods:

• Structure-based drug design
• Fragment-based drug discovery (FBDD)
• High-throughput screening (HTS)
• In silico approaches
• Development of covalent and non-covalent inhibitors

Main Results:

• Development of diverse Mpro inhibitors, including nirmatrelvir and ensitrelvir.
• Identification of novel scaffolds and optimized binding interactions.
• Non-covalent inhibitors show promise due to reversible binding and reduced off-target effects.

Conclusions:

• Mpro inhibitors are vital for treating SARS-CoV-2 infections and future pandemic preparedness.
• Ongoing research addresses challenges like bioavailability and resistance through prodrugs and combination therapies.
• Further optimization and novel strategies are needed to enhance therapeutic efficacy.